Metastatic Pheochromocytoma/Paraganglioma with Bulky, Symptomatic, or Rapidly Progressive Disease

This protocol addresses patients with metastatic pheochromocytoma or paraganglioma (mPPGL) who present with bulky disease — defined as many large metastases — or with symptomatic or rapidly progressive disease, a subpopulation requiring prompt systemic intervention.

Clinical scenario Cytotoxic chemotherapy is recommended as first-line treatment in this setting. The criteria that define this population — bulky disease (many large metastases), significant symptoms, or rapid progression — are each recognised as independent indications to initiate systemic therapy by consensus.

Treatment approach (partial overview) Systemic cytotoxic chemotherapy is the cornerstone of management. The approach involves combination cytotoxic regimens, and an alternative oral alkylating agent is also recognised. Ensuring adequate alpha-blockade is an important consideration in patients receiving cytotoxic chemotherapy.

Full regimen details, sequencing, dosing, and clinical decision logic are in the complete protocol →

Instant Access to Structured Evidence-Based Regimens

References

Cytotoxic chemotherapy should be considered first line when patients have bulky disease (defined as many large metastases) (significant majority) or symptomatic or rapidly progressive disease (consensus).

Systemic treatment for mPPGL may include the use of cytotoxic chemotherapies such as cyclophosphamide/vincristine/dacarbazine (CVD) or temozolomide-based treatments.

Temozolomide is a newer oral alkylating agent that has shown efficacy in pancreatic NETs (ECOG 2211).

Another reason to ensure α-blockade in patients receiving cytotoxic chemotherapy.

DOI: 10.1097/MPA.0000000000001792

View source ↗